APO Research, Inc.

APO RESEARCH · REPORT

OAB Treatment

Selected research

Market Outlook & Growth Opportunities

Global OAB Treatment Market Outlook and Growth Opportunities 2026

Market perspective

The global OAB Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for OAB Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OAB Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OAB Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the OAB Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the OAB Treatment market include Astellas Pharma, Kyorin Pharmaceutical, AbbVie, Pfizer, Johnson & Johnson and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global OAB Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OAB Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OAB Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global OAB Treatment market.

OAB Treatment Segment by Company

Astellas Pharma

Kyorin Pharmaceutical

AbbVie

Pfizer

Johnson & Johnson

Teva

OAB Treatment Segment by Type

Botox

Mirabegron

Anticholinergics

Others

OAB Treatment Segment by Application

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

OAB Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global OAB Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the OAB Treatment key companies, revenue, market share, and recent developments.

3. To split the OAB Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions OAB Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify OAB Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze OAB Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OAB Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OAB Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OAB Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global OAB Treatment industry.

Chapter 3: Detailed analysis of OAB Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of OAB Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of OAB Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. OAB Treatment Industry Trends Table 2. OAB Treatment Industry Drivers Table 3. OAB Treatment Industry Opportunities and Challenges Table 4. OAB Treatment Industry Restraints Table 5. Global OAB Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global OAB Treatment Revenue Share by Company (2021-2026) Table 7. Global OAB Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global OAB Treatment Key Company Manufacturing Base & Headquarters Table 9. Global OAB Treatment Company, Product Type & Application Table 10. Global OAB Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global OAB Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Botox Table 15. Significant Companies of Mirabegron Table 16. Significant Companies of Anticholinergics Table 17. Significant Companies of Others Table 18. Global OAB Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global OAB Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global OAB Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global OAB Treatment Sales Value Share by Type (2021-2026) Table 22. Global OAB Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Idiopathic Overactive Bladder Table 24. Significant Companies of Neurogenic Overactive Bladder Table 25. Global OAB Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global OAB Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global OAB Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global OAB Treatment Sales Value Share by Application (2021-2026) Table 29. Global OAB Treatment Sales Value Share by Application (2027-2032) Table 30. Global OAB Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global OAB Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global OAB Treatment Sales Value Share by Region (2021-2026) Table 33. Global OAB Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global OAB Treatment Sales Value Share by Region (2027-2032) Table 35. Global OAB Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global OAB Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global OAB Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global OAB Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global OAB Treatment Sales Value Market Share by Country (2027-2032) Table 40. Astellas Pharma Company Information Table 41. Astellas Pharma Business Overview Table 42. Astellas Pharma OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Astellas Pharma OAB Treatment Product Portfolio Table 44. Astellas Pharma Recent Development Table 45. Kyorin Pharmaceutical Company Information Table 46. Kyorin Pharmaceutical Business Overview Table 47. Kyorin Pharmaceutical OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Kyorin Pharmaceutical OAB Treatment Product Portfolio Table 49. Kyorin Pharmaceutical Recent Development Table 50. AbbVie Company Information Table 51. AbbVie Business Overview Table 52. AbbVie OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. AbbVie OAB Treatment Product Portfolio Table 54. AbbVie Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer OAB Treatment Product Portfolio Table 59. Pfizer Recent Development Table 60. Johnson & Johnson Company Information Table 61. Johnson & Johnson Business Overview Table 62. Johnson & Johnson OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Johnson & Johnson OAB Treatment Product Portfolio Table 64. Johnson & Johnson Recent Development Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva OAB Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva OAB Treatment Product Portfolio Table 69. Teva Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. OAB Treatment Product Image Figure 2. Global OAB Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OAB Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global OAB Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Botox Image Figure 8. Mirabegron Image Figure 9. Anticholinergics Image Figure 10. Others Image Figure 11. Global OAB Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global OAB Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global OAB Treatment Sales Value Share by Type (2021-2032) Figure 14. Idiopathic Overactive Bladder Image Figure 15. Neurogenic Overactive Bladder Image Figure 16. Global OAB Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global OAB Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global OAB Treatment Sales Value Share by Application (2021-2032) Figure 19. Global OAB Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global OAB Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America OAB Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America OAB Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe OAB Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe OAB Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific OAB Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific OAB Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America OAB Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America OAB Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa OAB Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa OAB Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt OAB Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt OAB Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt OAB Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Botox
  • Mirabegron
  • Anticholinergics
  • Others
Applications
  • Idiopathic Overactive Bladder
  • Neurogenic Overactive Bladder
Companies covered
  • Astellas Pharma
  • Kyorin Pharmaceutical
  • AbbVie
  • Pfizer
  • Johnson & Johnson
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global OAB Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global OAB Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 OAB Treatment Market Dynamics
  1. 2.1 OAB Treatment Industry Trends
  2. 2.2 OAB Treatment Industry Drivers
  3. 2.3 OAB Treatment Industry Opportunities and Challenges
  4. 2.4 OAB Treatment Industry Restraints
3 OAB Treatment Market by Company
  1. 3.1 Global OAB Treatment Company Revenue Ranking in 2025
  2. 3.2 Global OAB Treatment Revenue by Company (2021-2026)
  3. 3.3 Global OAB Treatment Company Ranking (2024-2026)
  4. 3.4 Global OAB Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global OAB Treatment Company Product Type and Application
  6. 3.6 Global OAB Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global OAB Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 OAB Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 OAB Treatment Market by Type
  1. 4.1 OAB Treatment Type Introduction
  2. 4.1.1 Botox
  3. 4.1.2 Mirabegron
  4. 4.1.3 Anticholinergics
  5. 4.1.4 Others
  6. 4.2 Global OAB Treatment Sales Value by Type
  7. 4.2.1 Global OAB Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global OAB Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global OAB Treatment Sales Value Share by Type (2021-2032)
5 OAB Treatment Market by Application
  1. 5.1 OAB Treatment Application Introduction
  2. 5.1.1 Idiopathic Overactive Bladder
  3. 5.1.2 Neurogenic Overactive Bladder
  4. 5.2 Global OAB Treatment Sales Value by Application
  5. 5.2.1 Global OAB Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global OAB Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global OAB Treatment Sales Value Share by Application (2021-2032)
6 OAB Treatment Regional Value Analysis
  1. 6.1 Global OAB Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OAB Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global OAB Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global OAB Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America OAB Treatment Sales Value (2021-2032)
  7. 6.3.2 North America OAB Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe OAB Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe OAB Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific OAB Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific OAB Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America OAB Treatment Sales Value (2021-2032)
  16. 6.6.2 South America OAB Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa OAB Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa OAB Treatment Sales Value Share by Country, 2025 VS 2032
7 OAB Treatment Country-level Value Analysis
  1. 7.1 Global OAB Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global OAB Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global OAB Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global OAB Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA OAB Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA OAB Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA OAB Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada OAB Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada OAB Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada OAB Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico OAB Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico OAB Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico OAB Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany OAB Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany OAB Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany OAB Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France OAB Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France OAB Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France OAB Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. OAB Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. OAB Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. OAB Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy OAB Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy OAB Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy OAB Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain OAB Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain OAB Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain OAB Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia OAB Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia OAB Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia OAB Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands OAB Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands OAB Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands OAB Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries OAB Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries OAB Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries OAB Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China OAB Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China OAB Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China OAB Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan OAB Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan OAB Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan OAB Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea OAB Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea OAB Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea OAB Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India OAB Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India OAB Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India OAB Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia OAB Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia OAB Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia OAB Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia OAB Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia OAB Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia OAB Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil OAB Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil OAB Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil OAB Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina OAB Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina OAB Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina OAB Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile OAB Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile OAB Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile OAB Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia OAB Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia OAB Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia OAB Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru OAB Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru OAB Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru OAB Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia OAB Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia OAB Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia OAB Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel OAB Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel OAB Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel OAB Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE OAB Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE OAB Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE OAB Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey OAB Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey OAB Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey OAB Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran OAB Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran OAB Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran OAB Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt OAB Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt OAB Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt OAB Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma OAB Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma OAB Treatment Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Kyorin Pharmaceutical
  8. 8.2.1 Kyorin Pharmaceutical Company Information
  9. 8.2.2 Kyorin Pharmaceutical Business Overview
  10. 8.2.3 Kyorin Pharmaceutical OAB Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Kyorin Pharmaceutical OAB Treatment Product Portfolio
  12. 8.2.5 Kyorin Pharmaceutical Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie OAB Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie OAB Treatment Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer OAB Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer OAB Treatment Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson OAB Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson OAB Treatment Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva OAB Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva OAB Treatment Product Portfolio
  36. 8.6.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.